Skip to content
ClinCalc Pro
Menu
Angiotensin II Receptor Blocker (ARB) — Hypertension / Raynaud's / Marfan Syndrome

Losartan

Brand names: Cozaar

Losartan is an oral angiotensin-II receptor blocker used for hypertension, diabetic nephropathy, and heart failure, including in patients intolerant of ACE inhibitors.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively blocks the angiotensin-II type-1 (AT1) receptor, causing vasodilatation, reduced aldosterone secretion and lower blood pressure without affecting bradykinin metabolism.

Prescribing in practice

  • Contraindicated in pregnancy because it can cause foetal harm, and it should be stopped if pregnancy is planned or confirmed.
  • It can cause hyperkalaemia and acute kidney injury, particularly with renal artery stenosis, volume depletion, or concurrent potassium-raising drugs or NSAIDs.
  • Do not combine with an ACE inhibitor or aliskiren because dual renin-angiotensin blockade increases the risk of hyperkalaemia, hypotension and renal impairment.

Monitoring

Monitor blood pressure, renal function and serum potassium, especially after initiation or dose changes.

Counselling the patient

  • Tell your doctor at once if you become or plan to become pregnant.
  • Dizziness can occur initially, particularly on standing; rise slowly.

Evidence & guidelines

Supported by major outcome trials in hypertension and diabetic nephropathy and recommended in NICE hypertension guidance.

Reference: LIFE Trial; COMPARE Trial (Marfan); NICE NG136 (Hypertension); BSR/BHPR Raynaud's Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.